Your browser doesn't support javascript.
Delayed mortality among solid organ transplant recipients hospitalized for COVID-19.
Heldman, Madeleine R; Kates, Olivia S; Safa, Kassem; Kotton, Camille N; Multani, Ashrit; Georgia, Sarah J; Steinbrink, Julie M; Alexander, Barbara D; Blumberg, Emily A; Haydel, Brandy; Hemmige, Vagish; Hemmersbach-Miller, Marion; La Hoz, Ricardo M; Moni, Lisset; Condor, Yesabeli; Flores, Sandra; Munoz, Carlos G; Guitierrez, Juan; Diaz, Esther I; Diaz, Daniela; Vianna, Rodrigo; Guerra, Giselle; Loebe, Matthias; Yabu, Julie M; Kramer, Kailey Hughes; Tanna, Sajal D; Ison, Michael G; Rakita, Robert M; Malinis, Maricar; Azar, Marwan M; McCort, Margaret E; Singh, Pooja P; Velioglu, Arzu; Mehta, Sapna A; van Duin, David; Goldman, Jason D; Lease, Erika D; Wald, Anna; Limaye, Ajit P; Fisher, Cynthia E.
  • Heldman MR; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Kates OS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Safa K; Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
  • Kotton CN; Massachusetts General Hospital, Boston, MA, USA.
  • Multani A; Massachusetts General Hospital, Boston, MA, USA.
  • Georgia SJ; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Steinbrink JM; Massachusetts General Hospital, Boston, MA, USA.
  • Alexander BD; Division of Infectious Diseases, Duke University, Durham, NC, USA.
  • Blumberg EA; Division of Infectious Diseases, Duke University, Durham, NC, USA.
  • Haydel B; Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Hemmige V; Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Hemmersbach-Miller M; Division of Infectious Disease, Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, NY, USA.
  • La Hoz RM; Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA.
  • Moni L; Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Condor Y; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Flores S; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Munoz CG; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Guitierrez J; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Diaz EI; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Diaz D; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Vianna R; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Guerra G; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Loebe M; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Yabu JM; University of Miami/Jackson Memorial Hospital, Miami, FL, USA.
  • Kramer KH; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Tanna SD; Transplant Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA.
  • Ison MG; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Rakita RM; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Malinis M; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Azar MM; Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • McCort ME; Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Singh PP; Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Velioglu A; Division of Nephrology, University of New Mexico, Albuquerque, NM, USA.
  • Mehta SA; Marmara University, School of Medicine, Department of Internal Medicine, Division of Nephrology, Istanbul, Turkey.
  • van Duin D; NYU Langone Transplant Institute, New York, NY, USA.
  • Goldman JD; Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA.
  • Lease ED; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Wald A; Swedish Medical Center, Seattle, WA, USA.
  • Limaye AP; Division of Pulmonology, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Fisher CE; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Clin Infect Dis ; 2022 Feb 25.
Article in English | MEDLINE | ID: covidwho-1713630
ABSTRACT

INTRODUCTION:

Most studies of solid organ transplant (SOT) recipients with COVID-19 focus on outcomes within one month of illness onset. Delayed mortality in SOT recipients hospitalized for COVID-19 has not been fully examined.

METHODS:

We used data from a multicenter registry to calculate mortality by 90 days following initial SARS-CoV-2 detection in SOT recipients hospitalized for COVID-19 and developed multivariable Cox proportional-hazards models to compare risk factors for death by days 28 and 90.

RESULTS:

Vital status at day 90 was available for 936 of 1117 (84%) SOT recipients hospitalized for COVID-19 190 of 936 (20%) died by 28 days and an additional 56 of 246 deaths (23%) occurred between days 29 and 90. Factors associated with mortality by day 90 included age > 65 years [aHR 1.8 (1.3-2.4), p =<0.001], lung transplant (vs. non-lung transplant) [aHR 1.5 (1.0-2.3), p=0.05], heart failure [aHR 1.9 (1.2-2.9), p=0.006], chronic lung disease [aHR 2.3 (1.5-3.6), p<0.001] and body mass index ≥ 30 kg/m 2 [aHR 1.5 (1.1-2.0), p=0.02]. These associations were similar for mortality by day 28. Compared to diagnosis during early 2020 (March 1-June 19, 2020), diagnosis during late 2020 (June 20-December 31, 2020) was associated with lower mortality by day 28 [aHR 0.7 (0.5-1.0, p=0.04] but not by day 90 [aHR 0.9 (0.7-1.3), p=0.61].

CONCLUSIONS:

In SOT recipients hospitalized for COVID-19, >20% of deaths occurred between 28 and 90 days following SARS-CoV-2 diagnosis. Future investigations should consider extending follow-up duration to 90 days for more complete mortality assessment.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Prognostic study Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Prognostic study Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid